Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke - Wikidata - thesis-toulmin - TriplyDB

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

http://www.wikidata.org/entity/Q24646522

about

Interventions for deliberately altering blood pressure in acute stroke Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus Adenosine and hypoxia-inducible factor signaling in intestinal injury and recovery Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes Secondary stroke prevention: challenges and solutions TIA Management: Should TIA Patients be Admitted? Should TIA Patients Get Combination Antiplatelet Therapy?Long-Term Antiplatelet Mono- and Dual Therapies After Ischemic Stroke or Transient Ischemic Attack: Network Meta-Analysis Immune interventions in stroke Antiplatelet therapy for carotid artery stenting Comparative effectiveness and implementation research: directions for neurology Anti-platelet therapy: phosphodiesterase inhibitors.Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis Pain following stroke: a population-based follow-up study Joint Commission primary stroke center certification does not affect proband enrollment: the siblings with ischemic stroke study The Secondary Prevention of Small Subcortical Strokes (SPS3) study.Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design.Individual patient data meta-analysis of antiplatelet regimens after noncardioembolic stroke or TIA: rationale and design.Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis.Adenosine: an old drug newly discovered.Remote Assessment of Platelet Function in Patients with Acute Stroke or Transient Ischaemic Attack Association of Optimal Combination Drug Treatment with Obesity Status among Recent Ischemic Stroke Patients: Results of the Vitamin Intervention for Stroke Prevention (VISP) Trial.Effects of clopidogrel added to aspirin in patients with recent lacunar stroke Symptomatic Carotid Artery Stenosis: Surgery, Stenting, or Medical Therapy?Dual antiplatelet therapy after noncardioembolic ischemic stroke or transient ischemic attack: pros and cons Probucol plus cilostazol attenuate hypercholesterolemia‑induced exacerbation in ischemic brain injury via anti-inflammatory effects Purinergic signaling during inflammation.2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by repres Preventing recurrent cerebrovascular events in patients with stroke or transient ischemic attack: the current data.Development, expansion, and use of a stroke clinical trials resource for novel exploratory analyses.Evidence-based management of carotid artery disease Predictors of mortality in patients with lacunar stroke in the secondary prevention of small subcortical strokes trial.What is better antiplatelet agent to prevent recurrent stroke?Dual antiplatelet therapy in secondary prevention of ischemic stroke: a ghost from the past or a new frontier?Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials Intensified secondary prevention intending a reduction of recurrent events in TIA and minor stroke patients (INSPiRE-TMS): a protocol for a randomised controlled trial.Dipyridamole with low-dose aspirin augments the infarct size-limiting effects of simvastatin Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study Low-molecular-weight heparin or dual antiplatelet therapy is more effective than aspirin alone in preventing early neurological deterioration and improving the 6-month outcome in ischemic stroke patients.Antiplatelets in secondary stroke prevention Intracranial atherosclerotic disease.

P2860

Q24193073-E2045ECE-4E41-441E-AB65-09DCF2E0C85C Q24203035-C1FB71E0-C8CD-4AE5-94FD-AA3251776B97 Q24620924-54F37B07-A4F8-4C22-AC19-502B3861754A Q24645205-3686631A-463E-4E68-9A7D-75ABFFAE519C Q26795568-FFB2C29D-E774-4BEF-8010-6AE891BE032C Q26796466-CFA702B6-9359-4B0D-A515-CCD5B6320CD3 Q26797510-74961B3C-EA63-43B7-BD33-3E9A4126C150 Q26797993-EC79A20E-9715-4153-9272-35EEC455A00C Q26852304-B29A47A2-A7E3-4765-9B83-B805CEB128EE Q27010166-EBFB30B7-F79F-4655-86F8-8316527A4CD6 Q27687228-33AD43FD-EE3E-4CE3-9A43-4E89B70B4B75 Q28076042-B866FFCD-E132-4941-8F8B-7FF7EBC4BA1C Q28742725-536474B9-1507-485D-A64C-CE1F7D68FB33 Q30438484-BDF9C71B-C0D5-4AA0-8C9D-FCCC00A35CE6 Q30596571-742C3733-14C2-432A-A957-16509B9333BD Q30644831-1F59DC74-FD2B-4775-A72C-CEB78F69C351 Q30987806-9CBB9590-6A79-4BE1-A3B1-D6F763B1D0BC Q33390176-21A5668C-C444-4A0C-A7CC-D61B63D84D0E Q33555006-54E5E022-874E-4030-B8EF-9B479050A8BE Q33775718-243D1282-4E21-44E3-A239-A7B9F6798C07 Q33783585-C5E4418A-1D11-404A-A492-D279F53D27A8 Q33792318-58B5D05F-831D-41D5-832C-6E04F74B1F06 Q33871078-98CCE804-2DBE-4EC1-A49E-35053D14030C Q33911647-798CFA00-F7F9-426B-8367-E2B968411DDA Q34000340-E88C2BB7-DF8E-461B-8AC9-8BAA8081518D Q34034751-C5D22533-4663-42F0-AE76-34B47C095D8D Q34046881-6888E57B-6E79-48BB-BAD8-061D485A90F7 Q34092629-481F5C43-E21B-45BD-AFC7-DF1D9E33029B Q34134653-36D72D8E-B450-4620-952F-20C588E0440D Q34175306-F0729517-9112-47C7-AAB2-CF0C39740329 Q34244196-40008CC7-892F-49BD-A6E1-49865792C7B0 Q34288489-2DD74E90-38B3-4196-9F5A-B99C0FCC36A7 Q34479105-FBFBA6AD-4E83-4B32-97A9-B6FE1E31D86F Q34527764-2FF8DD6C-81E8-4C59-B12E-385679DBE2FD Q34561255-891F7957-783A-4DD1-BCD1-C446CA1FA3D0 Q34634865-DCE2A282-BB63-4450-AD21-848C022EC774 Q34635205-2FECB8A6-628D-4243-A86C-6BB88FB9A1BE Q34996542-512D143D-54D4-4143-BF6E-8215E751D111 Q35091647-B1D519D5-9793-4EAC-8C29-5EB5F6BEB97F Q35109949-78EA890E-2840-41F1-B6FD-F56DE3ED73A7

P2860

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

http://www.wikidata.org/entity/Q24646522

description

2008 nî lūn-bûn

@nan

2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

@ast

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

@en

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

@nl

type

label

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

@ast

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

@en

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

@nl

prefLabel

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

@ast

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

@en

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

@nl

P1433

Q24646522-81698057-3DC2-4C56-8E0E-1BF4296CBAE4

P1476

Q24646522-66EDCF07-98A6-4AA1-8045-62B704FA9AB6

P2093

Q24646522-168CAD5E-56AA-499D-961A-06252BB2744D

Q24646522-2BEDAED8-B1BE-4293-B789-A7F9D26F6F1F

Q24646522-2CD926AB-05F8-4BE1-9235-C4F53AA1BA01

Q24646522-3E86B69C-A9C1-4A9E-AF25-311767FD1644

Q24646522-49700D1D-3456-4A3E-95BC-1A73BE0864E4

Q24646522-568E0783-457B-41A2-A1ED-89B69BF38BD8

Q24646522-58651D33-6082-482C-A3BA-B016BC60FD49

Q24646522-6C0F2A86-DA47-4F41-BEF9-10F2E34EF004

Q24646522-6CF7C905-14D4-4D72-8B40-9671F25DF84D

Q24646522-6E4A38EB-5FFD-45E1-82A3-CF610A38E769

P2860

Q24646522-003589B2-86E0-4E86-AC0F-2AB1E234F507

Q24646522-09CFF1B9-2688-4A31-8FC7-C94305533D85

Q24646522-10B5A31E-6747-404C-9A4F-741FC1F0E31E

Q24646522-16EA8DE5-4108-492E-9127-C9D41AFE9EBF

Q24646522-2DB60648-68E7-4E3A-9A1A-48929600B92E

Q24646522-3D72DD61-60B2-41A3-8F7B-DDAA6154E344

Q24646522-40A30EA3-D214-4204-8D2B-2992419B5A6E

Q24646522-5101BB3B-407D-4C87-A44E-9D4780260D23

Q24646522-61F3C648-72BA-46E0-84C8-A840EB01D7CA

Q24646522-6BEE703D-FA31-46A6-8BCE-557149727088

P304

Q24646522-CB976BE8-1A6D-486C-A8AE-829F07C6F8B2

P31

Q24646522-1BE8D6FE-44D1-4023-B4EB-7ACFAF40EDE9

P3181

Q24646522-D2693815-CE39-45B9-9884-A6A1959B4B82

P356

Q24646522-47A69793-28D4-43CF-A9B1-791207C26665

P407

Q24646522-CA22D67C-15A3-4DF4-ABA9-405C2A9CA5A5

P433

Q24646522-7419563A-16C4-4703-A749-A93369B4A8D0

P478

Q24646522-0059F5F6-A887-45B0-92D8-4489301F3F21

P50

Q24646522-066DE8A6-2885-42DA-9756-C773FC444822

Q24646522-14BEBCC4-5A99-4AE7-A40E-3BE667CAF2A3

Q24646522-3DF6D154-4770-406B-8A08-8734FB59953F

Q24646522-47874782-D856-4099-9F8E-48DDF165F6E0

Q24646522-5EED7FE7-D268-452F-AB49-1826A2C7DD9B

Q24646522-664134CB-0812-4824-8780-5422803F742F

Q24646522-757502D3-9FF2-40E8-BBF7-733C5BE43FC2

Q24646522-993D83B7-53E9-45C7-8ABB-F19EDDF4A60F

Q24646522-A8B27251-02F9-4348-810D-DCF21947643D

P577

Q24646522-DA4F814A-BB18-4985-922C-0A315CFD5E81

P698

Q24646522-3AA6B7F7-BC5B-44FA-8A73-8724066EFF40

P921

Q24646522-2D5150EF-7475-49DE-BD02-1DBCB09D83A2

Q24646522-C3890F12-2795-4A66-B568-0BF74BA8B382

P932

Q24646522-65101729-2972-4AF2-90FB-CB5FBA12FB50

P3181

P356

P1433

The New England Journal of Medicine

P1476

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

@en

P2093

Bernard P L Chan

http://www.w3.org/2001/XMLSchema#string

Byung-Woo Yoon

http://www.w3.org/2001/XMLSchema#string

Cam Vandermaelen

http://www.w3.org/2001/XMLSchema#string

Chuanzhen Lu

http://www.w3.org/2001/XMLSchema#string

Conrado Estol

http://www.w3.org/2001/XMLSchema#string

Daniel Cotton

http://www.w3.org/2001/XMLSchema#string

Danilo Toni

http://www.w3.org/2001/XMLSchema#string

Gregory W Albers

http://www.w3.org/2001/XMLSchema#string

Karin Hermansson

http://www.w3.org/2001/XMLSchema#string

Lutz Hilbrich

http://www.w3.org/2001/XMLSchema#string

P2860

Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial

FUNCTIONAL EVALUATION: THE BARTHEL INDEX

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial

Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis

P304

1238-51

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4830605

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA0805002

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

359

http://www.w3.org/2001/XMLSchema#string

P50

Hans-Christoph Diener

Jacques De Keyser

Geoffrey A. Donnan

Philip M W Bath

P577

2008-09-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18753638

http://www.w3.org/2001/XMLSchema#string

P921

P932

2714259

http://www.w3.org/2001/XMLSchema#string